Surprisingly, genetic variables such as the APOE e4 gene (which increases the risk of developing AD and therefore cognitive deficits) does not seem to differentiate individuals regarding their financial capacity deficits [35], while data on beta-amyloid and tau for AD come only from a small-scale study of Greek AD patients and show no relationship between financial deficits and these biomarkers [36]. This evidence concerns the gene MAPT and Alzheimer disease.